The global psoriatic arthritis treatment market size is anticipated to touch USD 13.12 billion by the end of 2027 on account of the increasing prevalence of psoriatic arthritis. According to a published report by Fortune Business Insights titled, “Psoriatic Arthritis Treatment Market Size, Share & COVID-19 Impact Analysis, By Drugs Class (Non-steroidal Anti-inflammatory Drugs (NSAIDS), Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Others), By Route of Administration (Oral, Parenteral, and Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Forecast, 2020-2027,” the value of this market was USD 6.35 billion in the year 2019. The forecast period is set between 2020 and 2027 and the market is expected to rise at a CAGR of 9.5%.
Get Sample PDF Brochure:
https://www.fortunebusinessinsights.com/enquiry/sample/psoriatic-arthritis-treatment-market-101066
Most of the businesses today are affected by the coronavirus pandemic. The imposition of stringent government regulations for controlling the widespread use of this virus has majorly impacted the world economy. Some of the businesses that are operating from homes are barely able to generate meagre revenue.
Fortune Business Insights is offering detailed analysis on the impact of the COVID-19 pandemic on different markets. These reports will assist financers and other candidates to study the current situation and accordingly plan ahead of the future.
Drivers & Restraints
Rising Prevalence of Psoriasis Arthritis to Augment Growth
The growing geriatric population and the increasing prevalence of psoriatic arthritis are the key factors boosting the global psoriatic arthritis treatment market growth. This disease is likely to prevail in people leading a stressful lifestyle. This, coupled with the increasing affordability of biologic products and new product launches, will also contribute positively to the growth of the market.
On the negative side, the impact of the COVID-19 pandemic has reduced the urgency of other diseases and therefore hampered the growth of the market for psoriatic arthritis. Moreover, the high cost of biologic products used for treating this kind of disease may pose a major challenge to the growth of this market.
Nevertheless, the continuously rising patient pool and the increasing preference for the use of biological treatment products especially by dermatologists are likely to create lucrative growth opportunities for the market in the coming years.
To get to know more about the short-term and long-term impact of COVID-19 on this market,
Please Visit: https://www.fortunebusinessinsights.com/industry-reports/psoriatic-arthritis-treatment-market-101066
Segmentation-
DMARDs Segment to Dominate Market Owing to Increasing Adoption of Biological Therapies
Among all drug class types, the biologic disease modifying anti-rheumatic drugs (DMARDs) segment earned the largest psoriatic arthritis treatment market share in 2019. This is accountable to the increasing adoption of biological therapies, a factor that is attributable to its efficacy towards disease management.
Regional Analysis-
Rising Adoption of Biological Therapies to help North America Continue Dominating Market
Among all regions, North America accounted for the largest share on account of the massive investments in research and development of therapeutic options and coupled with the increasing adoption of biological therapies to treat psoriasis arthritis. Moreover, the presence of large manufacturers and the continuous number of clinical trials and drug approvals by the U.S. Food and Drug Administration will further help this region dominate the market in the coming years.
Europe ranks second in terms of market size whereas Asia Pacific market is likely to emerge as the fastest growing region in the forecast duration on account of the improving healthcare infrastructure, rise in medical expenditure, and the entry of novel biologics.
Speak To Our Analyst:
Competitive Landscape-
Players Focusing on Getting FDA Approvals of their Products to Stay Ahead in the Competition
The competitive landscape of the global psoriatic arthritis treatment market is consolidated in nature on account of the presence of a few players. Among them, AbbVie is holding the leading position in the market owing to its most popular brand, Humira used for treating psoriatic arthritis. Some of the other players are engaging in launching products and anticipating FDA approvals to gain a competitive edge in the market competition.
Industry Developments
December 2017 – The U.S. Food and Drug Administration permitted the use of Infliximab, an antibody for fighting diseases such as plague psoriasis, ankylosing spondylitis, Crohn’s disease, and others.
August 2019 – Otezla was acquired by Amgen for USD 13.4 billion cash. This new therapy will help to strengthen the overall portfolio of Amgen.
List of Companies Profiled in the market for psoriatic arthritis treatment:
- Bayer AG (Leverkusen, Germany)
- Bristol-Myers Squibb Company (New York, United States)
- AstraZeneca (Cambridge, United Kingdom)
- Johnson & Johnson Services, Inc. (New Jersey, United States)
- Pfizer Inc. (New York, United States)
- Eli Lilly and Company (Indiana, United States)
- Novartis AG (Basel, Switzerland)
- GlaxoSmithKline plc. (Brentford, United Kingdom)
- Hoffmann-La Roche Ltd (Basel, Switzerland)
- Amgen (Califormia, United States)
- Sanofi (Paris, France)
Quick Buy – Psoriatic Arthritis Treatment Market Research Report:
https://www.fortunebusinessinsights.com/checkout-page/101066
Table Of Contents :
- Introduction
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- Prevalence of Psoriatic Arthritis for Key Countries/Region
- Recent Industry Developments Such as Partnerships, Mergers & Acquisitions, New Product Launches Etc.
- Pipeline Analysis for Key Companies
- Regulatory Framework by Key Countries
- Impact of COVID-19 on Psoriatic Arthritis Treatment Market
- Global Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2016-2027
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Drug Class
- Non-steroidal Anti-inflammatory Drugs (NSAIDS)
- Non-biologic Disease Modifying Anti-Rheumatic Drugs
- Biologic Disease Modifying Anti-Rheumatic Drugs
- Market Analysis, Insights and Forecast – By Route of Administration
- Oral
- Parenteral
- Topical
- Market Analysis, Insights and Forecast – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market Analysis, Insights and Forecast – By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- North America Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2016-2027
- Key Findings / Summary
- Market Analysis – By Drug Class
- Non-steroidal Anti-inflammatory Drugs (NSAIDS)
- Non-biologic Disease Modifying Anti-Rheumatic Drugs
- Biologic Disease Modifying Anti-Rheumatic Drugs
- Market Analysis – By Route of Administration
- Oral
- Parenteral
- Topical
- Market Analysis – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online pharmacies
- Market Analysis – By Country
- U.S.
- Canada
- Europe Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2016-2027
- Key Findings / Summary
- Market Analysis – By Drug Class
- Non-steroidal Anti-inflammatory Drugs
- Non-biologic Disease Modifying Anti-Rheumatic Drugs
- Biologic Disease Modifying Anti-Rheumatic Drugs
- Market Analysis – By Route of Administration
- Oral
- Parenteral
- Topical
- Market Analysis – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online pharmacies
- Market Analysis – By Country/Sub-region
- U.K.
- Germany
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific Psoriatic Arthritis Treatment Market Analysis, Insights and Forecast, 2016-2027
- Key Findings / Summary
- Market Analysis – By Drug Class
- Non-steroidal Anti-inflammatory Drugs (NSAIDS)
- Non-biologic Disease Modifying Anti-Rheumatic Drugs
- Biologic Disease Modifying Anti-Rheumatic Drugs
- Market Analysis – By Route of Administration
- Oral
- Parenteral
- Topical
- Market Analysis – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online pharmacies
- Market Analysis – By Country/Sub-region
- Japan
- China
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
Ask for Customization of this Report:
About Us:
Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245